Characteristic | Total | High BPTF | Low BPTF | χ2 | P-values |
---|---|---|---|---|---|
Percent of sample, n (%) | Â | 55 (50.5) | 54 (49.5) | Â | Â |
Sex, n (%) | Â | Â | Â | 3.305 | 0.069 |
 Male | 53 (48.6) | 22 (40.0) | 31 (57.4) |  |  |
 Female | 56 (51.4) | 33 (60.0) | 23 (42.6) |  |  |
Age (months), n (%) | Â | Â | Â | 1.155 | 0.283 |
  < 18 | 18 (16.5) | 7 (12.7) | 11 (20.4) |  |  |
  ≥ 18 | 91 (83.5) | 48 (87.3) | 43 (79.6) |  |  |
Staging, n (%) | Â | Â | Â | 6.694 | 0.010* |
 I-III/IVs | 55 (50.5) | 21 (38.2) | 34 (63.0) |  |  |
 IV | 54 (49.5) | 34 (61.8) | 20 (37.0) |  |  |
Risk group, n (%) | Â | Â | Â | 5.731 | 0.017* |
 LR or IR | 54 (49.5) | 21 (38.2) | 33 (61.1) |  |  |
 HR | 55 (50.5) | 34 (61.8) | 21 (38.9) |  |  |
MYCN status, n (%) | Â | Â | Â | 0.057 | 0.810 |
 Amplification | 15 (13.8) | 8 (14.5) | 7 (13.0) |  |  |
 Not amplification | 94 (86.2) | 47 (85.5) | 47 (87.0) |  |  |
1p36 status, n (%) | Â | Â | Â | 0.052 | 0.819 |
 LOH | 25 (23.6) | 13 (24.5) | 12 (22.6) |  |  |
 No loss | 81 (76.4) | 40 (75.5) | 41 (77.4) |  |  |
11q23 status, n(%) | Â | Â | Â | 2.771 | 0.096 |
 LOH | 34 (32.1) | 21 (39.6) | 13 (24.5) |  |  |
 No loss | 72 (67.9) | 32 (60.4) | 40 (75.5) |  |  |
PHOX2B, n (%) | Â | Â | Â | 3.303 | 0.069 |
  = 0 | 51 (46.8) | 21 (38.2) | 30 (55.6) |  |  |
  > 0 | 58 (53.2) | 34 (61.8) | 24 (44.4) |  |  |
LDH (U/L), n (%) | Â | Â | Â | 1.216 | 0.749 |
  ≤ 295 | 36 (33.0) | 18 (32.7) | 18 (33.4) |  |  |
 295–500 | 24 (22.0) | 10 (18.2) | 14 (25.9) |  |  |
 500–1500 | 32 (29.4) | 18 (32.7) | 14 (25.9) |  |  |
  > 1500 | 17 (15.6) | 9 (16.4) | 8 (14.8) |  |  |
NSE (ng/l), n (%) | Â | Â | Â | 4.863 | 0.088 |
  ≤ 25 | 26 (23.9) | 12 (21.8) | 14 (25.9) |  |  |
 25–100 | 24 (22.0) | 8 (14.5) | 16 (29.7) |  |  |
  > 100 | 59 (54.1) | 35 (63.7) | 24 (44.4) |  |  |
Primary tumor site, n (%) | Â | Â | Â | 6.161 | 0.013* |
 Retroperitoneum and adrenal glands | 71 (65.1) | 42 (76.4) | 29 (53.7) |  |  |
 Mediastinum/Pelvic cavity/Neck | 38 (34.9) | 13 (23.6) | 25 ((46.3) |  |  |
Tumor size (cm), n (%) | Â | Â | Â | 6.262 | 0.044* |
  ≤ 5 | 26 (23.9) | 9 (16.4) | 17 (31.5) |  |  |
 5–10 | 43 (39.4) | 20 (36.4) | 23 (42.6) |  |  |
  > 10 | 40 (36.7) | 26 (47.2) | 14 (25.9) |  |  |
Number of organs with metastasis, n (%) | Â | Â | Â | 2.711 | 0.100 |
  ≤ 3 | 60 (55.0) | 26 (47.3) | 34 (63.0) |  |  |
  > 3 | 49 (45.0) | 29 (52.7) | 20 (37.0) |  |  |
BM metastasis, n (%) | Â | Â | Â | Â | Â |
 Yes | 49 (45.0) | 30 (54.5) | 19 (35.2) | 4.127 | 0.042* |
 No | 60 (55.0) | 25 (45.5) | 3535353564.8) |  |  |